{"result": "(\"entity\"<|>MEN1<|>EVENT<|>MEN1 is a syndrome characterized by the presence of two or more tumors in specific glands, caused by mutations in the MEN1 gene.)\n##\n(\"entity\"<|>CDKN1B<|>GENE<|>CDKN1B is a gene that encodes the p27 protein and is associated with mutations in some patients with MEN1 phenotype.)\n##\n(\"entity\"<|>RET<|>GENE<|>RET is a proto-oncogene that, when mutated, causes MEN2 syndrome, which is inherited in an autosomal dominant manner.)\n##\n(\"entity\"<|>SDHB<|>GENE<|>SDHB is a gene that encodes a subunit of the succinate dehydrogenase enzyme and is linked to familial paraganglioma syndrome type 4.)\n##\n(\"entity\"<|>AIRE<|>GENE<|>AIRE is a gene associated with autoimmune conditions and is mentioned in the context of genetic studies related to MEN syndromes.)\n##\n(\"entity\"<|>HYPERPARATHYROIDISM<|>EVENT<|>Hyperparathyroidism is a condition often associated with MEN1 syndrome, characterized by excessive secretion of parathyroid hormone.)\n##\n(\"entity\"<|>ADENOMA<|>EVENT<|>Adenoma refers to a benign tumor that can occur in the pituitary gland, often seen in patients with MEN1.)\n##\n(\"entity\"<|>HYPERCALCEMIA<|>EVENT<|>Hypercalcemia is a condition of elevated calcium levels in the blood, commonly associated with hyperparathyroidism.)\n##\n(\"entity\"<|>HYPOTIROIDISM<|>EVENT<|>Hypothyroidism is a condition where the thyroid gland does not produce enough hormones, mentioned in the context of patient symptoms.)\n##\n(\"entity\"<|>HYPERPROLACTINEMIA<|>EVENT<|>Hyperprolactinemia is a condition of elevated prolactin levels in the blood, which can lead to various symptoms including erectile dysfunction.)\n##\n(\"relationship\"<|>MEN1<|>CDKN1B<|>CDKN1B mutations are found in some patients with MEN1 phenotype, indicating a genetic link<|>7)\n##\n(\"relationship\"<|>MEN1<|>RET<|>RET mutations cause MEN2 syndrome, which is related to MEN1 in terms of genetic syndromes<|>5)\n##\n(\"relationship\"<|>MEN1<|>HYPERPARATHYROIDISM<|>Hyperparathyroidism is a common condition associated with MEN1 syndrome<|>8)\n##\n(\"relationship\"<|>HYPERPARATHYROIDISM<|>ADENOMA<|>Adenomas in the pituitary gland can lead to hyperparathyroidism in MEN1 patients<|>6)\n##\n(\"relationship\"<|>HYPERPARATHYROIDISM<|>HYPERCALCEMIA<|>Hyperparathyroidism often results in hypercalcemia<|>9)\n##\n(\"relationship\"<|>HYPERPROLACTINEMIA<|>HYPOTIROIDISM<|>Hypothyroidism can be associated with hyperprolactinemia in patients<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: íada\n             negativo.                                                                                                      clásica de candidiasis mucocutánea, hipoparatiroidismo autoinmunitario y enfermedad\n         B. Solo se repetiría el estudio del gen MEN1 si uno de los diagnósticos fuese de tumor                             de Addison, que constituyen tres de los componentes más habituales del trastorno. Los\n             neuroendocrino.                                                                                                pacientes tienen riesgo de presentar enfermedades autoinmunitarias de prácticamente\n         C. Hay que estudiar el cromosoma 12 para descartar mutaciones de CDKN1b.                                           cualquier órgano. Se hereda de forma recesiva y es secundario a mutaciones del gen AIRE.\n         D.  En más del 50% de los pacientes con MEN1 no se identifica una mutación en el gen                               Referencias:\n             MEN1.                                                                                                          • Arnold A. Multiple endocrine neoplasia type 1: Definition and genetics. Drezner MK, Raby BA, eds. UptoDate. Waltham, MA: UpToDate Inc.\n                                                                                                                              https://www.uptodate.com (acceso 14 de junio de 2019).\n         En un paciente de 25 años de edad con hiperparatiroidismo y adenoma hipofisario                                    • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n     39                                                                                                                     • Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Capítulo 3. Neoplasia Endocrina Múltiple. Madrid: Sociedad\n         productor de GH, sin alteración detectada en el gen de la menina, ¿qué estudio                                       Española de Endocrinología y Nutrición; 2015. Disponible en: https://manual.seen.es.\n         genético solicitaría?\n         A. RET.                                                                                                        40  Paciente varón de 51 años, diagnosticado de hiperparatiroidismo a los 44 años,\n         B. CDKN1B.                                                                                                         con hipercalcemia grave y litiasis renal. Tratado mediante paratiroidectomía\n         C. SDHB.                                                                                                           subtotal (anatomía patológica: dos adenomas paratiroideos). Hiperparatiroidismo\n         D.  AIRE.                                                                                                          persistente en tratamiento médico con buen control. En su visita programada\n                                                                                                                            refiere disfunción eréctil y disminución de la libido de 9 meses de evolución. Se\n                                                                                                                            objetiva hiperprolactinemia (PRL 673 ng/ml) con hipogonadismo e hipotiroidismo\n         COMENTARIO                                                                                                         central con eje adrenal normal e IGF-1 en límite inferior de lo normal. En este\n         El diagnóstico clínico de síndrome de MEN1 se realiza en un sujeto (caso índice) si presen-                        contexto, ¿cuál de los siguientes enunciados es falso?\n         ta dos o más tumores de los considerados clásicos de MEN1 (en las glándulas paratiroides,                          A. Posiblemente tenga un macroprolactinoma.\n         hipófisis anterior y células de los islotes pancreáticos). Se produce por mutaciones en el                         B. Sería conveniente valorar los niveles de calcitonina.\n         gen MEN1 que es un gen supresor de tumores.\n         En aproximadamente el 10% de los pacientes no se identifica ninguna mutación en el gen                             C. Es conveniente realizar un estudio genético de mutacionesdel gen MEN1.\n         MEN1, pero sí en otros genes como el CDKN1B que codifica la proteína p27. Se han descrito                          D.  Es probable que tenga o que desarrolle en el seguimiento un tumor neuroendocrino\n         mutaciones en este gen en un             3%   de  los pacientes con fenotipo MEN1, negativos para                      gastroenteropancreático.\n         mutaciones en el gen MEN. A esta nueva entidad clínica se la denomina MEN4                           y es una\n         enfermedad autosómica dominante. No se ha descrito un fenotipo característico de este\n         síndrome, sino que es igual al de MEN1.\n         También se han descrito mutaciones en los genes p15, p21 y p18 en menos del 1% de los\n         pacientes con fenotipos similares al síndrome de MEN1.\n         El síndrome de MEN2 (tanto el tipo 2A como 2B) se produce por mutaciones en el protoon-\n         cogén RET que se transmiten de forma autosómica dominante.\n         Las mutaciones en el gen SDHB (succinate dehydrogenase complex subunit B gene), que\n         codifica una de las subunidades de la enzima succinato-deshidrogenasa o complejo mito-\n         condrial II, ocasionan el síndrome de paraganglioma familiar tipo 4. Estos pacientes desa-\n\n\n\n408                                                                                                                                                                                                                                             409\n                                                                                                                                                                                                                                                   409\n---\n                                                                                                                                                    METABOLISMO FOSFOCÁLCICO, TUMORES                                                                7\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}